Trial reportNeuropsychiatric disease and treatment2025
Examination on the Acceptability, Feasibility and Effectiveness of a Digital Cognitive Training Software in Patients With Stable Schizophrenia in China.
Trial report in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy Analysis of Evidence-Based Nursing Combined With Computer-Assisted Cognitive Correction Therapy on Cognitive Function and Quality of Life in Patients With Schizophrenia.Actas espanolas de psiquiatria · 2026Article
- Family caregivers' willingness to use online psychological therapy for individuals with mental illness in China: a cross-sectional study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This single-arm study aimed to explore the acceptability and effectiveness of a digital cognitive training software (IBT-004) in patients with stable schizophrenia. Methods: This study conducted an 8-week home-based cognitive training program, IBT-004, for patients with stable schizophrenia. Forty-seven participants were recruited from Peking University Sixth Hospital and Hebei Provincial Mental Health Center. IBT-004 focused on improving cognitive function through independent tasks. Cognitive function was assessed using the Chinese Brief Neurocognitive Suite of Tests (C-BCT) and self-report scales, with additional evaluation of the program's acceptability and feasibility. Results: After 8 weeks of cognitive training, patients showed significant improvements in total cognitive scores, Digit Span, and Trial Making Test (P < 0.05). Subjective cognitive distress significantly decreased (Z = -3.758, P < 0.001). Age (B = -0.532, β = -0.476, P < 0.05) and training duration (B = 0.273, β = 0.340, P < 0.05) were significant predictors of Continuous Performance Test scores (F = 3.884, P < 0.05). Patients showed high acceptance of the software. Enjoyment scores (1-5 scale) ranged from 3.46 to 4.14, and difficulty scores (1-5 scale) ranged from 2.31 to 2.86, with no significant changes over time (P < 0.05). The average training time was 36.89 hours, and adherence reached 92.24%, indicating strong engagement and compliance. Conclusion: This study showed that a home-based online cognitive training program improved cognitive function in patients with stable schizophrenia. Significant gains were seen in overall cognitive scores, processing speed, and attention. Participants also reported reduced cognitive distress. Younger age and longer training hours were linked to better outcomes. The program had high adherence, supported by personalized adjustments and engaging features. These results confirm the program's feasibility and effectiveness for cognitive improvement in schizophrenia. Clinical Trials Registration: ChiCTR2200055930.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.